Agfa HealthCare announces today, that it has acquired the TIP Group, which is based in Graz, Austria. This merger of two healthcare pioneers will broaden Agfa HealthCare’s portfolio with specialized Business Intelligence and ERP solutions for hospitals.
Specialized tools for Business Intelligence
“The merger with the TIP Group will give us access to a specialist in hospital Business Intelligence, with solutions that will extend our global offering in a meaningful way,” says Winfried Post, CEO and General Manager, Agfa HealthCare GmbH. “Business Intelligence solutions are ever-more important for hospitals. The increasing cost pressures in healthcare will only be efficiently managed in the future using specialized tools. With this acquisition, we now have a solution that is tailored to the data integration and analysis needs of the hospital, allowing us to generate an even higher added value for healthcare facilities.”
Agfa HealthCare (agfahealthcare.com) and the TIP Group (tip-ag.com) both have long-standing experience in healthcare and in the optimization of processes. Combined with deep insight into hospital workflows, this will enable the advantages of a joint future will be realized quickly, and an extremely powerful team will emerge from the merger.
Extended portfolio of solutions
“The acquisition by Agfa HealthCare opens up new possibilities for our comprehensive product portfolio,” says Heimo Babcicky, chairman and founder of the TIP Group. “Agfa HealthCare is a strong and solid partner for us and for our customers, which enables us to jointly offer a larger portfolio. In this way, our solutions improve and our customers benefit from our cooperation.”
The new partners will begin working together immediately, to mutually make the change for a successful future.
Source: Agfa HealthCare
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.